-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nivolumab in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nivolumab in Relapsed Acute Myeloid Leukemia Drug Details: Nivolumab (Opdivo, Opdyta) is a human IgG4...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Basal Cell Carcinoma (Basal Cell Epithelioma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Basal Cell Carcinoma (Basal Cell Epithelioma) Drug Details: CMP-001 (CYT-003) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erenumab in Pain
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Erenumab in Pain Drug Details: Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human immunoglobulin G2 (IgG2)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efineptakin Alfa in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Efineptakin Alfa in Non-Small Cell Lung Cancer Drug Details: Efineptakin alfa (GX-I7) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Camrelizumab in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Camrelizumab (Airuika) is a humanized monoclonal antibody...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) Drug Details: Rhenium (186Re) obisbemeda...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Recurrent Glioblastoma Multiforme (GBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Recurrent Glioblastoma Multiforme (GBM) Drug Details: Relatlimab (BMS-986016) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Psilocybin in Smoking Cessation
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Psilocybin in Smoking Cessation Drug Details: Psilocybin is under investigation for the treatment of obsessive...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ifinatamab Deruxtecan in Squamous Non-Small Cell Lung Cancer Drug Details: Ifinatamab deruxtecan (DS-7300) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Magrolimab in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Magrolimab in Relapsed Acute Myeloid Leukemia Drug Details: Magrolimab is under development for the treatment...